- Home
- ABLV vs ACRV Comparison
ABLV vs ACRV Comparison
Compare ABLV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- ACRV
- Stock Information
- Founded
- ABLV 2015
- ACRV 2018
- Country
- ABLV China
- ACRV United States
- Employees
- ABLV N/A
- ACRV N/A
- Industry
- ABLV
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ABLV
- ACRV Health Care
- Exchange
- ABLV Nasdaq
- ACRV Nasdaq
- Market Cap
- ABLV 51.4M
- ACRV 47.8M
- IPO Year
- ABLV N/A
- ACRV 2022
- Fundamental
- Price
- ABLV N/A
- ACRV $1.88
- Analyst Decision
- ABLV
- ACRV Buy
- Analyst Count
- ABLV 0
- ACRV 6
- Target Price
- ABLV N/A
- ACRV $17.75
- AVG Volume (30 Days)
- ABLV 12.8K
- ACRV 556.9K
- Earning Date
- ABLV 04-23-2025
- ACRV 11-12-2025
- Dividend Yield
- ABLV N/A
- ACRV N/A
- EPS Growth
- ABLV N/A
- ACRV N/A
- EPS
- ABLV 0.05
- ACRV N/A
- Revenue
- ABLV $114,319,869.00
- ACRV N/A
- Revenue This Year
- ABLV N/A
- ACRV N/A
- Revenue Next Year
- ABLV N/A
- ACRV $805.34
- P/E Ratio
- ABLV $20.65
- ACRV N/A
- Revenue Growth
- ABLV N/A
- ACRV N/A
- 52 Week Low
- ABLV $0.55
- ACRV $1.05
- 52 Week High
- ABLV $1.77
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- ABLV N/A
- ACRV 69.16
- Support Level
- ABLV N/A
- ACRV $1.82
- Resistance Level
- ABLV N/A
- ACRV $1.99
- Average True Range (ATR)
- ABLV 0.00
- ACRV 0.11
- MACD
- ABLV 0.00
- ACRV 0.02
- Stochastic Oscillator
- ABLV 0.00
- ACRV 86.23
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.